title: [Gastric MALT lymphoma: anatomo-clinical data and outcome of early stage H. pylori-associated gastric MALT-lymphoma resistant to treatment].
abstract: OBJECTIVE
  To describe the clinical, endoscopic and histological particularities of early stage HP associated gastric MALT lymphoma resistant to anti Hp treatment and identify predicting factors of resistance.
  
  
  METHODS
  We retrospectively studied 12 patients with primary low grade gastric localized MALT lymphoma treated with anti HP treatment and diagnosed at La Rabta Hospital from 1999 to 2009.
  
  
  RESULTS
  The ultrasonography was normal in 5 patients between the 6 responding patients. Perigastric lymph nodes were found in non responders (33.3%). Hp eradication was achieved in 66% of patients not responding while Hp was eradicated in 100% of responders. The two non-responding patients with failure of eradication of Hp had a strain resistant to Clarithromycin Hp.
  
  
  CONCLUSIONS
  Predicting factors of failure of anti HP: HP resistance to antibiotics, the proximal head, and the presence of perigastric lymph nodes. Recently, chromosomal aberrations and immune-histochemical markers have been implicated as factors of non response to anti Hp.
authors.affiliation: Hopital La Rabta, Tunis, Tunisie.
authors.forename: Ines
authors.initials: I
authors.lastname: Chelly
authors.forename: Olfa
authors.initials: O
authors.lastname: Adouni
authors.forename: Sofiane
authors.initials: S
authors.lastname: Chouaib
authors.forename: Haifa
authors.initials: H
authors.lastname: Azouz
authors.forename: Haifa
authors.initials: H
authors.lastname: Nfoussi
authors.forename: Slim
authors.initials: S
authors.lastname: Haouet
authors.forename: Moncef
authors.initials: M
authors.lastname: Zitouna
authors.forename: Nidhameddine
authors.initials: N
authors.lastname: Kchir
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003625:Data Collection; D004352:Drug Resistance, Microbial / Q000502:physiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D016480:Helicobacter pylori / Q000502:physiology*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D008297:Male; D009367:Neoplasm Staging; D009853:Omeprazole / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D009853:Omeprazole